Immix Biopharma, Inc. IMMX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -74.4%-19.5pp | -54.9%+128pp | -182.5%-20.5pp | -162%-50.6pp | -111.4%+34.3pp | |
| Liquidity | ||||||
| Current ratio | 8.8×-1.3× | 10×+8.5× | 1.5×+0.3× | 1.2×-0.6× | 1.8×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×-0.1× | 0.1×-0.1× | 0.2×+0.1× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $1.52-46.4% | $2.85+999% | $0.26+66.8% | $0.16-52.0% | $0.32-31.1% | |
| Valuation | ||||||
| Market capitalization | $691.97M+1,008% | $275.6M+304% | $68.27M+9.3% | $62.45M+34.1% | $46.57M-23.0% | |
| Price / book | 8.2×+1.7× | 2.9×-5.3× | 8.3×-5.2× | 13.4×+8.6× | 4.9×+0.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immix Biopharma, Inc.'s ratios come from?
- Every ratio is computed from Immix Biopharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.